Syntheses and biological studies of nitroimidazole conjugated heteroscorpionate ligands and related Cu(I) and Cu(II) complexes

Copper Coordination Compounds as Biologically Active Agents

“…Once inside the cell, the nitroradical anion interacts with DNA and destroys the double helix. Cu(II) coordination compounds 104 and 105 and Cu(I) coordination compounds 106 and 107 with ligands based on 5-nitroimidazole were synthesized in [118] (Figure 32). The COX-2 level in lipopolysaccharide-stimulated RAW macrophages was investigated on a flow cytometer after treatment with coordination compounds 102 and 103, and the anti-inflammatory potential of coordination compound 102 was confirmed.…”

“…Once inside the cell, the nitroradical anion interacts with DNA and destroys the double helix. Cu(II) coordination compounds 104 and 105 and Cu(I) coordination compounds 106 and 107 with ligands based on 5-nitroimidazole were synthesized in [118] ( Figure 32). Table 12.…”

“…Table 12. MTT data of coordination compounds 104-107 after 72 h of incubation [118]. 2.1 ± 1.1 1.9 ± 0.9 107 Cu(I) 4.9 ± 1.…”

Synthesis and Cytotoxic Activity Evaluation of New Cu(I) Complexes of Bis(pyrazol-1-yl) Acetate Ligands Functionalized with an NMDA Receptor Antagonist

“…Bis(azol-1-yl) carboxylic acids are convenient starting materials for the preparation of conjugated heteroscorpionate systems, due to the κ 3 -NNO coordination behavior of bis(azol-1-yl) methanes and to the presence of a carboxylic function suitable for the coupling with bioactive molecules [31][32][33][34][35][36]. We recently reported the synthesis and characterization of glucosamine and 5-nitroimidazole bifunctional ligands and the related Cu(I) and Cu(II) complexes, as well as a brief investigation of their cytotoxic activity toward human tumor cell lines [37][38][39].…”

“…Based on our experience [37] Cu(I) complexes might be more active anticancer agents than the corresponding Cu(II) ones [46,47]. Therefore, the aim of the present research was to synthesize and to assess the anticancer potential of novel Cu(I) complexes based on NMDA-ANT-conjugated bis(pyrazol-1-yl) acetate (L NMDA or L 2NMDA ) and phosphane ligands (compounds 3, 4, 7, and 8; Figure 1), as well as the related Cu(I) phosphane complexes with the bis(pyrazol-1-yl) carboxylic acids LH and L 2 H (compounds 1, 2, 5, and 6; Figure 1).…”